Innate Pharma

Report Publication Announcement • Nov 7, 2012

INNATE PHARMA TO MEET ITS RETAIL INVESTORS AT ACTIONARIA ON NOVEMBER 23 & 24

Marseilles, France, November 7, 2012

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces its second participation to Actionaria, a forum dedicated to meeting with individual investors, on November 23 & 24, in Paris.

"The potential for growth and innovation of companies within our sector is attractive to retail investors. Innate continues to outperform the sector's stockmarket performance, in large part because the market values our two partnerships with major pharma leaders, the potential of our proprietary pipeline as well as our financial security", commented Hervé Brailly, CEO of Innate Pharma "Our retail shareholders base represents a significant part of our capital and is a strength on which we intend to build for the long term through events like Actionaria".

Innate Pharma representatives will be at booth A20, level 1 on 23 and 24 November. Hervé Brailly will participate in a number of conferences on Friday, November 23:

• 2:25 to 2:40pm : Presidents' Agora
• 3:05 to 3:20pm: "Midcaps, the economic support of the regions?"
• 3:30 to 4:30pm: Conference-debate : "Midcaps: a socially responsible investment"
• 5:30 to 6:30pm: Conference "Biotech, growth stocks to enhance your portfolio"

To receive electronic invitations to Actionaria, please visit our website (www.innate pharma.com). To receive paper invitations, please send an email to investors@innate-pharma.com, stating your postal address and the desired number of invitations.

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the Company's website and contact the investor relations team by writing to investors@innate-pharma.com. They can also become member of the shareholders' club (in French only) by following the link: http://www.innatepharma.com/fr/finances/club-actionnaires.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approach has been validated by licence agreements with two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 81 employees as at September 30, 2012.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

For additional information, please contact:

Innate Pharma ATCG Press Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mob.: +33 (0)6 26 94 18 53 investors@innate-pharma.com mb@atcg-partners.com

Marielle Bricman